title: Commentary for Clancy, P et al., ARBs and ERK activation: new insights on human atherosclerosis.
authors.affiliation: University of Kentucky, Lexington, KY, USA. Electronic address: SeanThatcher@uky.edu.
authors.forename: Sean
authors.initials: S
authors.lastname: Thatcher
mesh_terms: D015059:1-Sarcosine-8-Isoleucine Angiotensin II / Q000494:pharmacology*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D001713:Biphenyl Compounds / Q000494:pharmacology*; D016207:Cytokines / Q000378:metabolism*; D004730:Endothelium, Vascular / Q000187:drug effects*; D005260:Female; D006801:Humans; D000077405:Irbesartan; D008297:Male; D019950:Mitogen-Activated Protein Kinase 1 / Q000378:metabolism*; D048052:Mitogen-Activated Protein Kinase 3 / Q000378:metabolism*; D010455:Peptides / Q000494:pharmacology*; D012084:Renin-Angiotensin System / Q000187:drug effects*; D013777:Tetrazoles / Q000494:pharmacology*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001713:Biphenyl Compounds; D016207:Cytokines; C556151:DX600 peptide; D010455:Peptides; D013777:Tetrazoles; D015059:1-Sarcosine-8-Isoleucine Angiotensin II; C535150:MAPK1 protein, human; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D000077405:Irbesartan
keywords: Angiotensin II; Angiotensin receptor blocker; Atherosclerosis; Inflammation